SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum driven by a newly announced collaboration with NVIDIA to integrate its QNX safety-critical OS into advanced edge AI systems, fueling a community-led surge in retail interest and trending status. Investors are increasingly optimistic about the companys turnaround, pointing to growing royalty backlogs, cybersecurity demand, and the stock's recent break past key resistance levels as signs of a long-awaited revaluation.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a sharp rally following a rapid management response to a short-seller report, which included plans to redomicile in the U.S. and clarify tax status regarding PFIC concerns. The community is actively discussing a potential short squeeze, highlighting strong institutional accumulation and the stock's positioning within the high-demand AI data center infrastructure sector.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing a surge in trading volume and bullish sentiment driven by clinical trial progress, including favorable updates on their prostate cancer treatment that have stoked speculation about potential partnership or buyout interest. The community is actively discussing the stock's undervaluation compared to its large market potential, with many investors pointing to recent institutional accumulation and the expectation of upcoming regulatory milestones as catalysts for a potential short squeeze.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing massive retail and institutional attention following a new executive order that fast-tracks regulatory pathways and funding for psychedelic drug research, specifically highlighting ibogaine. The community is actively debating the stock's potential for a short squeeze driven by its extremely low tradable float, while some investors urge caution regarding potential dilution and the long-term reality of clinical timelines.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is experiencing heightened investor interest and increased volume following a definitive agreement to acquire Serra Verde Group for approximately $2.8 billion, a move described by the community as a major strategic pivot to secure non-Asian supply chain dominance. While some market participants are debating the short-term impacts of the associated share dilution, sentiment remains largely focused on the potential for long-term supply chain leverage and the stock's role in the broader shift toward domestic critical mineral independence.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI Life Sciences N.V.

ATAI is trending as investors react to a potential $2 billion buyout process for its lead BPL-003 asset and excitement surrounding the company's Q2 Phase 3 trial initiation. The community is actively discussing the stock's long-term potential as a psychedelic platform, with many highlighting its institutional backing and the significant regulatory tailwinds shifting the sector's outlook.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is seeing significant volatility as investors react to a sudden leadership shakeup involving the resignation of the CEO and CFO, alongside ongoing concerns about delayed power milestones and the search for an anchor tenant. While some community members are treating the pullback as a buying opportunity given the project's long-term scale and infrastructure potential, others are increasingly skeptical, pointing to the lack of revenue and the potential for further downside before stabilization.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is currently surging as investors react to positive regulatory shifts regarding peptide distribution and a strengthening partnership narrative with Novo Nordisk. The community is actively discussing a potential short squeeze, with many participants highlighting the stock's high short interest and expressing bullish sentiment about the company's long-term growth as it pivots toward a broader health and wellness ecosystem.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant volatility following a failed orbital deployment of a satellite by Blue Origin, leading to intense community debate over execution risks versus the company's long-term growth thesis. While some investors are viewing the price drop as a strategic buying opportunity supported by insurance coverage and a robust production pipeline, others remain critical of the company's reliance on external launch providers and the resulting timeline delays.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is experiencing high volatility and significant momentum as investors anticipate imminent Phase 3 clinical trial results for its psilocybin-based treatment, COMP360. The community is closely debating the clinical trial data readout and the stock's potential as a takeover candidate, with many traders closely watching for price breakouts tied to regulatory tailwinds and speculative short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in the Companys flagship ingredient, Niagen...

JPMorgan Chase & Co. Makes New $3.68 Million Investment in Niagen Bioscience, Inc. $NAGE

JPMorgan Chase & Co. bought a new position in shares of Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) during the third quarter, according to the company in its most recent filing with the...

Niagen Bioscience's (NAGE) Buy Rating Reiterated at Canaccord Genuity Group

Canaccord Genuity Group restated a "buy" rating and issued a $13.00 price target on shares of Niagen Bioscience in a research note on Tuesday...

Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced OneSpaWorld (NASDAQ: OSW) as the...

Niagen Bioscience, Inc. (NASDAQ:NAGE) Short Interest Down 13.6% in March

Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 5,578,868...

Niagen Bioscience (NASDAQ:NAGE) Upgraded at Wall Street Zen

Wall Street Zen raised Niagen Bioscience from a "hold" rating to a "buy" rating in a research report on Saturday...

Niagen Bioscience Increases Share Repurchase Program to $20 Million

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has...

Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen, Contributing to 45 Published Clinical Studies

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research...

Niagen Bioscience Launches Niagen Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud, From Tru Niagen Powered by Patented Niagen

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Niagen Skincare...

HC Wainwright Issues Optimistic Outlook for NAGE Earnings

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - HC Wainwright increased their Q1 2026 earnings estimates for shares of Niagen Bioscience in a report released on Thursday, March 5th. HC...

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, Analytical Reference Standards and Services, and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The Pharmaceuticals segment focuses on the pharmaceutical development of NAD precursor portfolio for potential therapeutic applications in rare diseases. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

NAGE
Niagen Bioscience Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NAGE News

NAGENiagen Bioscience Inc